Calls for papers
-
CDMO Hovione has announced that former CEO Guy Villax will succeed Stefan Doboczky as chairman of the company’s board of directors, effective April 1, 2027. Villax served as CEO from 1997 until 2022 when he… Read more . . .
-
US-based startup LionBio, which describes itself as “The Nasal Peptide Company,” has published a video announcing the company’s launch with $6 million in seed funding and nose-to-brain delivery technology developed at Columbia University developed by… Read more . . .
-
Phillips Medisize, which completed its acquisition of inhalation CDMO Vectura in 2025, has announced the acquisition of all remaining portions of the former Vectura site in Chippenham, UK. The acquisition of Vectura originally included only… Read more . . .
-
Ethris has announced topline data from a Phase 2a challenge study of ETH47 mRNA-based antiviral in adults with mild-to-moderate asthma. According to Ethris, the trial demonstrated that ETH47 “was safe, well tolerated and showed antiviral… Read more . . .
-
The Dutch Central Committee on Research Involving Human Subjects has approved Abera Bioscience’s application for a Phase 1 clinical trial of its Ab-01.12 intranasal pneumococcal vaccine, the company said. According to Abera, the dose escalation… Read more . . .
-
Drug delivery specialist CDMO Kindeva has announced the appointment of Daniel Couto as Executive VP, Inhalation & Specialty Drug Delivery. Couto was most recently COO at Vedanta Biosciences. His prior experience includes executive positions at Vedanta,… Read more . . .
-
Cambridge Healthcare Innovations announced that its Quattrii blister-based DPI has been selected for delivery of inhaled dry powder formulations of biologics being developed by University College London professor Jenny Lam. CHI partnered with Aptar in… Read more . . .
-
1nhaler raises additional £2.2 million for development of its single-dose salbutamol (albuterol) DPI
1nhaler announced that it has closed a £2.2 million funding round led by Archangels, with the proceeds intended to support preparations for a clinical trial of its disposable, single-dose 1nhaler Salbutamol DPI with a goal… Read more . . .
-
Tiziana Life Sciences has announced that the Phase 2a INFORM-MS study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis met both of its primary endpoints, demonstrating significant reduction in microglial activation at Week… Read more . . .
-
Merck has announced the initiation of the Phase 3 ENHANCE-3 study of Ohtuvarye ensifentrine inhalation suspension, which is expected to enroll 2,136 COPD patients and will evaluate Ohtuvarye for the prevention of exacerbations. Merck acquired… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA